Prevention and Early Detection of Lung Cancer in Women
- Determine the ability of computed tomography (CT) to detect early lung parenchymal
abnormalities in women at high risk for lung cancer.
- Determine the number of abnormal findings detected by CT that develop into lung cancer
in these patients.
- Correlate these abnormalities with the presence of K-ras and p53 mutations in the
sputum and bronchoalveolar lavage in these patients.
- Develop and implement appropriate educational materials regarding lung cancer in women
and provide referrals to other programs, such as smoking cessation programs.
OUTLINE: Patients complete a questionnaire at baseline to assess demographics, medical
history, smoking history, menopausal status, estrogen therapy, and diet.
Patients then undergo a low-dose computed tomography (CT) scan without contrast. Patients
with normal CT results undergo additional CT scans every 12 months.
Patients with abnormal CT results undergo a diagnostic CT scan (in the absence of prior
studies). Patients with indeterminate nodules (less than 5 mm in size) undergo surveillance
CT studies within 3-4 months. If nodules remain unchanged in size, patients undergo
additional surveillance CT studies at 6 months and 1 year. Patients with lung parenchymal
abnormalities on CT suspicious for malignancy undergo a bronchoscopy with biopsy and
bronchoalveolar lavage (BAL). Patients with abnormal CT scan(s) and negative BAL for p53
and/or K-ras mutations or normal histology and positive BAL for K-ras and/or p53 mutations
undergo additional CT scans at 6 months and 1 year. Patients with biopsy-proven malignancy
after bronchoscopy are referred for definitive treatment.
PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.
Primary Purpose: Screening
Abraham Chachoua, MD
New York University School of Medicine
United States: Federal Government
|NYU School of Medicine's Kaplan Comprehensive Cancer Center||New York, New York 10016|